Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12Gastrointestinal 11Thoracic 9Genitourinary 7Lymphoid 6Gynecologic 6Sarcoma 4Head & Neck 4Tumor-Agnostic 3CNS 3Endocrine 2Other solid neoplasm 1Other neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma 1Lymphoma, B-Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fluorodeoxyglucose F18 × Other solid neoplasm × Clear all
NCT02599194 2019-01-03

18F-FSPG PET/CT for Cancer Patients on Therapy

Stanford University

Phase 2 Completed
7 enrolled 6 charts
BreastGenitourinaryLymphoidOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Lymphoma, B-Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡